Ophthotech Completes Patient Recruitment of the First Phase 3 Pivotal Trial of Fovista® Anti-PDGF Therapy in Combination with Lucentis® in Wet Age-Related Macular Degeneration Program

NEW YORK--(BUSINESS WIRE)--Ophthotech Corporation today announced the completion of patient recruitment of its first Phase 3 trial of Fovista® in combination with Lucentis® (ranibizumab).